PHOENIX was a Phase 2, open-label, multi-center, US-only trial with four separate cohorts of patients with ADPKD, IgAN, T1D CKD, or FSGS. Bardoxolone methyl treatment in patients with IgA nephropathy resulted in significant increase in kidney function as measured by eGFR at Week 12 from baseline.
- IgAN is the most prevalent primary chronic glomerular disease and affects approximately 120,000 patients in the US.
- Bardoxolone methyl treatment resulted in a significant eGFR increase of 8.0 mL/min/1.73 m² at Week 12 from baseline in patients with IgAN.
- Bardoxolone methyl was well-tolerated without any drug-related SAEs, changes in blood pressure, or evidence of fluid overload.